Articles

CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Current address: H3 Biomedicine, Cambridge, MA, USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Current address: Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Current Address: Department of Pathology, Mount Sinai Hospital, New York, NY, USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Current Address: Department of Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Current address: Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA
Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA, USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Vol. 105 No. 5 (2020): May, 2020 https://doi.org/10.3324/haematol.2019.216218